China’s pharmaceutical manufacturing areas began recovering from coronavirus-related travel restrictions in mid-February, with production back up to half the normal rate, says US Pharmacopeia CEO Ron Piervincenzi.
The USP could detect that by reviewing Chinese sales of its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?